when was the first glp 1 agonist approved of GLP-1RAs for treatment of type 2 diabetes. FDA US Food Continued growth for GLP-1 receptor
Description
Whether it is TIDM or TIIDM, if patients do not treat their hyperglycemia through appropriate medical interventions, they may face a series of severe consequences like blindness, kidney failure, or amputation.
Designed to complement your GLP-1 journey
Mechanistic hypotheses include reduced leptin-driven T-helper (Th)1/Th17 activity, improved adipokine balance, and modulation of gut-thyroid axis pathways
Understanding these interactions requires individualized provider guidance based on your complete medical history and current medication list
